Ipilimumab-Induced Neutropenia in Melanoma
Ipilimumab is a human monoclonal IgG1 antibody against CTLA-4 that has been shown to prolong the overall survival of advanced melanoma. The most common adverse events associated with ipilimumab are immune-related. Severe hematological toxicity is rare. We report a case of severe neutropenia followin...
Saved in:
Main Authors: | Makiko Ban-Hoefen MD (Author), Richard Burack MD (Author), Lynn Sievert NP (Author), Deepak Sahasrabudhe MD (Author) |
---|---|
Format: | Book |
Published: |
SAGE Publishing,
2016-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ipilimumab: Melanoma and beyond
by: Vishal Patel, et al.
Published: (2011) -
Use of ipilimumab in the treatment of melanoma
by: Acharya UH, et al.
Published: (2013) -
Profile of ipilimumab and its role in the treatment of metastatic melanoma
by: Patel SP, et al.
Published: (2011) -
Panhypopituitarism induced by ipilimumab
by: Miyu Shiratori, et al.
Published: (2020) -
Photosensitive Dermatitis Induced by Nivolumab/Ipilimumab Combination Therapy in a Patient with Malignant Melanoma
by: Yuri Sakaguchi, et al.
Published: (2020)